IMP: BOD resolution dated November 29, 2022
The Board resolution dated November 29, 2022, the Board of Directors of Imexpharm Corporation approved to use the Development Investment Fund to compensate for the Conpany’s operating expenses in 2022 with total amount of VND10,560,521,135.
HOSE
> C47: Approval for the extension of public offering Certificate (01/12/2022)
> HDB: Notice of collecting shareholders' written opinions (01/12/2022)
> HHS: Agreement with related party (01/12/2022)
> CTG: Approved agreements with VBI (01/12/2022)
> E1VFVN30: Report on result of transaction of related institution (HSC) (01/12/2022)
> FUEVFVND: Report on result of transaction of related institution (HSC) (01/12/2022)
> NVL: Report on result of transaction of related institution - Novagroup (01/12/2022)
> NVL: Report on results of trading of shares by Related Person - Cao Thi Ngoc Suong & Bui Cao Nhat Quan (01/12/2022)
> EVE: Report on result of trading of Shares of Related Person- Lee Je Won (01/12/2022)
> CII: Report on results of trading of shares by Related Person - Pham Thi Thuy Hang (01/12/2022)